

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/705, C12N 5/10, 15/12	A1	(11) International Publication Number: WO 96/30404 (43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: PCT/US96/03591 (22) International Filing Date: 15 March 1996 (15.03.96) (30) Priority Data: 08/414,625 31 March 1995 (31.03.95) US (71) Applicant: TULARIK, INC. [US/US]; 270 East Grand Avenue, South San Francisco, CA 94080 (US). (72) Inventors: GOEDDELL, David, V.; Tularik, Inc., 270 East Grand Avenue, South San Francisco, CA 94080 (US). HSU, Hailing; Tularik, Inc., 270 East Grand Avenue, South San Francisco, CA 94080 (US). (74) Agents: BREZNER, David, J. et al.; Flehr, Hohbach, Test, Albritton & Herbert, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: INTRACELLULAR SIGNALING PROTEINS AND METHODS OF USE		
(57) Abstract A novel family of intracellular signaling proteins, exemplified by a Tumor Necrosis Factor Receptor-1 Associated Death Domain protein (TRADD), share a common TRADD sequence and include transducers of signals that modulate cell growth, differentiation and apoptosis. As such, the TRADD proteins, TRADD-encoding nucleic acids, and natural TRADD intracellular binding targets provide both important targets and means for therapeutic intervention. In particular, the invention provides isolated TRADDs and TRADD fragments, nucleic acids encoding the subject TRADDs and TRADD fragments or capable of selectively hybridizing to such TRADD-encoding nucleic acids, vectors and cells comprising TRADD-encoding nucleic acids, and TRADD-specific binding reagents. These compositions find use in diagnostic and therapeutic methods for disease associated with undesirable cell growth, migration, differentiation and/or cytokine signal responsiveness and methods and compositions for identifying lead compounds and pharmacological agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Intracellular Signaling Proteins and Methods of Use

INTRODUCTION

Field of the Invention

The field of this invention is human intracellular death domain-containing signaling proteins.

Background

Tumor necrosis factor (TNF) is a cytokine produced mainly by activated macrophages. Two distinct TNF receptors of 55 kd (TNF-R1) and 75 kd (TNF-R2) have been identified. These TNF receptors are members of the larger TNF receptor superfamily which also includes the Fas antigen, CD27, CD30, CD40, and the low affinity nerve growth factor receptor. TNF-R1 is responsible for most of TNF's biological properties, including programmed cell death, antiviral activity and activation of the transcription factor NF- κ B in a wide variety of cell types. It also plays an essential role in host defense against microorganisms and bacterial pathogens. Mutagenesis studies have identified a "death domain" of approximately 80 amino acids near the C-terminus of TNF-R1 that is required for signaling antiviral activity and cell death. The death domain of TNF-R1 probably also triggers activation of an endosomal acidic sphingomyelinase (A-SMase). A homologous domain, that can also initiate programmed cell death, is found in the Fas antigen. The apoptosis induced by both TNF and Fas was recently shown to involve the activation of the interleukin-1 β converting enzyme (ICE) or an ICE-like cysteine protease (Tewari and Dixit, 1995). ICE is related in primary amino acid sequence to the *ced-3* gene product which plays an essential

role in programmed cell death in *C. elegans*. ICE has been predicted to be involved in mammalian programmed cell death (Yuan et al., 1993).

Identifying and developing new pharmaceuticals is a multibillion dollar industry in the U.S. Urgently needed are efficient methods of identifying pharmacological agents which, if amenable to automated, cost-effective, high throughput drug screening, would have immediate application in a broad range of domestic and international pharmaceutical and biotechnology drug development programs. As TNF is involved in the signaling of a number of cellular responses including cytotoxicity, anti-viral activity, immuno-regulatory activities and the transcriptional regulation of a number of genes, it is desired to identify agents which specifically modulate transduction of TNF signaling. Unfortunately, the TNF-R1-associated proteins involved in generating the various TNF-induced signals remain unknown; hence, the reagents necessary for the development of high-throughput screening assays for such therapeutics are unavailable.

Relevant Literature

VanArsdale and Ware (1994) *J Immunology* 153:3043-3050 describe proteins associated with TNF-R1. Rothe et al. (1994) *Cell* 78:681-692 report the identification of a family of putative signal transducers associated with the cytoplasmic domain of the 75 kD TNF-R2. The cloning and amino acid sequencing of TNF-R1 is disclosed in Schall et al (1990) *Cell* 61, 361 and Loetscher et al (1990) *Cell* 61, 351; the identification of a "death domain" in TNF-R1 is disclosed in Tartaglia et al. (1993) *Cell* 74:845-853. The cloning and amino acid sequencing of the Fas antigen is disclosed in Itoh et al (1991) *Cell* 66, 233-243; a mutational analysis of the Fas antigen is described in Itoh et al. (1993) *J Biol Chem* 268, 10932. For a recent review, see Smith et al. (1994) *Cell* 76:959-962.

SUMMARY OF THE INVENTION

The invention provides methods and compositions relating to a novel family of intracellular signaling proteins exemplified by a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD). The subject proteins share common TRADD sequences and include transducers of signals that

modulate cell growth, differentiation and apoptosis. As such, the subject TRADD proteins, TRADD-encoding nucleic acids, and natural TRADD intracellular binding targets provide both important targets and means for therapeutic intervention. In particular, the invention provides isolated TRADDs and TRADD fragments, nucleic acids encoding the subject TRADDs and TRADD fragments or capable of selectively hybridizing to such TRADD-encoding nucleic acids, vectors and cells comprising TRADD-encoding nucleic acids, and TRADD-specific binding reagents. The invention also provides diagnostic and therapeutic methods and compositions for disease associated with undesirable cell growth, migration, differentiation and/or cytokine signal responsiveness and methods and compositions for identifying lead compounds and pharmacological agents.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides methods and compositions relating to a novel family of intracellular signaling proteins comprising a TRADD or TRADD fragment, especially a TRADD Death Domain. The subject proteins include transducers and effectors of signals that modulate cellular function involving gene transcription, cell growth, differentiation, migration and apoptosis. In particular, TNF signaling is involved in tumoricidal activity, anti-infection activity (e.g. host immune responsiveness to pathogenic infections of HIV, *Helicobacter pylori*, *Mycobacterium tuberculosis*, etc.), cachexia associated with chronic disease, cartilage destruction (e.g. in rheumatoid arthritis), immune cell recruitment, sepsis and septic shock (e.g. adult respiratory distress syndrome), vascular disease (e.g. atherosclerosis), diabetes mellitus type I, multiple sclerosis, gastritis, etc.

The subject TRADD fragments have one or more TRADD-specific binding affinities, such as the ability to specifically bind at least one natural intracellular TRADD-specific binding target or a TRADD-specific binding agent such as a TRADD-specific antibody or a TRADD-specific binding agent identified in assays such as described below. Preferred TRADD fragments are capable of at least one of specifically binding another TRADD (oligomerizing), specifically binding TNF-R1, transducing TNF-R1 signaling, activating TRADD-specific transcription, activating TRADD-specific apoptosis, or inhibiting any of

the foregoing functions, or eliciting an antibody capable of specifically binding a TRADD.

Methods for making immunogenic peptides through the use of conjugates, adjuvants, etc. and methods for eliciting antibodies, e.g. immunizing rabbits, are well known. Convenient ways to verify the ability of a given TRADD fragment to specifically bind such targets include in vitro labelled binding assays such as described below. The specificity of TRADD fragment specific binding agents may be confirmed by ensuring non-cross-reactivity with non-TRADD related proteins and protein fragments such as TNF-R1 and Fas antigen death domains. Other natural TRADD binding targets are readily identified by screening cells, membranes and cellular extracts and fractions with the disclosed materials and methods and by other methods known in the art. For example, two-hybrid screening using TRADD fragments are used to identify intracellular targets which specifically bind such fragments.

The subject TRADD fragments maintain binding affinity of not less than three, preferably not less than two, more preferably not less than one order of magnitude less than the binding equilibrium constant of the corresponding full-length native TRADD to the binding target under similar conditions. Particular TRADD fragments or deletion mutants are shown to function in a dominant-negative fashion. Such fragments provide therapeutic agents, e.g. when delivered by intracellular immunization - transfection of susceptible cells with nucleic acids encoding such mutants.

The subject TRADD fragments are of length sufficient to provide a novel peptide: such peptides are at least 6, usually at least about 7, more usually at least about 8, most usually at least about 10 amino acids. The claimed TRADD and fragments thereof are isolated, partially pure or pure and are typically recombinantly produced. An "isolated" peptide is unaccompanied by at least some of the material with which it is associated in its natural state and constitutes at least about 0.5%, preferably at least about 2%, and more preferably at least about 5% by weight of the total protein (including peptide fragments) in a given sample; a partially pure peptide constitutes at least about 10%, preferably at least about 30%, and more preferably at least about 60% by weight of the total protein in a given sample; and a pure peptide constitutes at least about 70%, preferably at

least about 90%, and more preferably at least about 95% by weight of the total protein in a given sample. The TRADD fragments may be present in a free state or bound to other components such as blocking groups to chemically insulate reactive groups (e.g. amines, carboxyls, etc.) of the peptide, fusion peptides or polypeptides (i.e. the peptide may be present as a portion of a larger polypeptide), etc.

Preferred TRADD fragments derive at least in part from the TRADD death domain region. Particularly preferred TRADD death domain fragments comprise one or more conserved TRADD death domain peptides include from the N-terminal end of the Death Domain, VVNRPL (SEQUENCE ID NO:2, residues 209-214), DQQTRAR (SEQUENCE ID NO:2, residues 218-224), SVGLKWR (SEQUENCE ID NO:2, residues 225-231), VGRSLQR (SEQUENCE ID NO:2, residues 233-239), CRALRD (SEQUENCE ID NO:2, residues 241-246), PALDSL (SEQUENCE ID NO:2, residues 247-252), AYEYER (SEQUENCE ID NO:2, residues 253-258), GLYEQA (SEQUENCE ID NO:2, residues 260-265), FQLRRF (SEQUENCE ID NO:2, residues 266-272), QAEGRR (SEQUENCE ID NO:2, residues 274-280), TLQRLV (SEQUENCE ID NO:2, residues 281-286), EALEEN (SEQUENCE ID NO:2, residues 287-292) and ELTSLA (SEQUENCE ID NO:2, residues 293-298).

A wide variety of molecular and biochemical methods are available for generating and expressing TRADD fragments, see e.g. Molecular Cloning, A Laboratory Manual (2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor), Current Protocols in Molecular Biology (Eds. Ausubel, Brent, Kingston, More, Feidman, Smith and Stuhl, Greene Publ. Assoc., Wiley-Interscience, NY, NY, 1992) or that are otherwise known in the art. For example, TRADD or fragments thereof may be obtained by chemical synthesis, expression in bacteria such as *E. coli* and eukaryotes such as yeast, baculovirus, or mammalian cell-based expression systems, etc., depending on the size, nature and quantity of the TRADD or fragment.

The invention provides TRADD-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, TRADD-specific agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or

disease prognosis is associated with improper utilization of a pathway involving TRADD, e.g. TNFR1 activation, TNF expression, etc. Novel TRADD-specific binding agents include TRADD-specific antibodies and other natural intracellular binding agents identified with assays such as one- and two-hybrid screens, non-natural intracellular binding agents identified in screens of chemical libraries, etc.

Generally, TRADD-specificity of the binding target is shown by binding equilibrium constants. Such targets are capable of selectively binding a TRADD, i.e. with an equilibrium constant at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1} . A wide variety of cell-based and cell-free assays may be used to demonstrate TRADD-specific binding. Cell based assays include one, two and three-hybrid screens, mediating or competitively inhibiting TRADD-mediated transcription, etc. Preferred are rapid in vitro, cell-free assays such as mediating or inhibiting TRADD-protein (e.g. TRADD-TNFR1 death domain), immunoassays, etc. Other useful screening assays for TRADD/TRADD fragment-target binding include fluorescence resonance energy transfer (FRET), electrophoretic mobility shift analysis (EMSA), etc.

The invention also provides nucleic acids encoding the subject TRADD and fragments, which nucleic acids may be part of TRADD-expression vectors and may be incorporated into recombinant cells for expression and screening, transgenic animals for functional studies (e.g. the efficacy of candidate drugs for disease associated with expression of a TRADD), etc. Nucleic acids encoding TRADD containing proteins are isolated from eukaryotic cells, preferably human cells, by screening cDNA libraries with probes or PCR primers derived from the disclosed TRADD cDNAs. In addition, the invention provides nucleic acids sharing sufficient sequence similarity with that of one or more disclosed TRADD-encoding nucleic acids or fragment thereof to effect hybridization. Such substantially identical or homologous nucleic acids are capable of hybridizing to the TRADD-encoding nucleic acid defined by SEQUENCE ID NO: 1 or 3 under stringency conditions characterized by a hybridization buffer comprising 0% formamide in 0.9 M saline/0.09 M sodium citrate (SSC) buffer at a temperature of 37°C and remaining bound when subject to washing at 42°C with the SSC buffer at 37°C . Preferred nucleic acids will hybridize in a hybridization buffer comprising 20% formamide in 0.9 M saline/0.09 M sodium citrate (SSC) buffer at

a temperature of 42°C and remaining bound when subject to washing at 42°C with 2 X SSC buffer at 42°C. More preferred nucleic acids encode invariant TRADD sequences and a TRADD with 50% pair-wise identity to that of SEQUENCE ID NO:2.

The subject nucleic acids are isolated, meaning they comprise a sequence joined to a nucleotide other than that which it is joined to on a natural chromosome and usually constitutes at least about 0.5% , preferably at least about 2%, and more preferably at least about 5% by weight of total nucleic acid present in a given fraction. A partially pure nucleic acid constitutes at least about 10%, preferably at least about 30%, and more preferably at least about 60% by weight of total nucleic acid present in a given fraction. A pure nucleic acid constitutes at least about 80%, preferably at least about 90%, and more preferably at least about 95% by weight of total nucleic acid present in a given fraction.

The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, therapeutic nucleic acids, etc.; use in detecting the presence of TRADD Death Domain genes and gene transcripts, in detecting or amplifying nucleic acids encoding additional TRADD Death Domain homologs and structural analogs, and in gene therapy applications.

For example, therapeutic TRADD nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active TRADD. In particular, where cell-specific apoptosis or other limitation of cell growth is desired, e.g. neoproliferative disease, cytostatic TRADD Death Domain encoding nucleic acids are introduced into the targeted cell type. A wide variety of neoproliferative indications may be treated, either prophylactically or therapeutically with the subject compositions. Conditions for treatment include restenosis, where vascular smooth muscle cells are involved, inflammatory disease states, where endothelial cells, inflammatory cells and glomerular cells are involved, myocardial infarction, where heart muscle cells are involved, glomerular nephritis, where kidney cells are involved, transplant rejection where endothelial cells are involved, infectious diseases such as HIV infection where certain immune cells and other infected cells are involved, or the like.

In other situations where it is desired to reduce cytokine, particularly TNF, responsiveness, nucleic acids capable of inhibiting translation of a TRADD or TRADD fragment containing protein are introduced. These nucleic acids are typically antisense: single-stranded sequences comprising complements of the disclosed relevant TRADD fragment-encoding nucleic acid. Antisense modulation of the expression of a given TRADD fragment containing protein may employ TRADD fragment antisense nucleic acids operably linked to gene regulatory sequences. Cells are transfected with a vector comprising a TRADD fragment sequence with a promoter sequence oriented such that transcription of the gene yields an antisense transcript capable of binding to endogenous TRADD fragment containing protein encoding mRNA. Transcription of the antisense nucleic acid may be constitutive or inducible and the vector may provide for stable extrachromosomal maintenance or integration. Alternatively, single-stranded antisense nucleic acids that bind to genomic DNA or mRNA encoding a given TRADD fragment containing protein may be administered to the target cell, in or temporarily isolated from a host, at a concentration that results in a substantial reduction in expression of the targeted protein.

Various techniques may be employed for introducing of the nucleic acids into viable cells. The techniques vary depending upon whether one is using the subject compositions in culture or *in vivo* in a host. Various techniques which have been found efficient include transfection with a retrovirus, viral coat protein-liposome mediated transfection, see Dzaou et al., *Trends in Biotech* 11, 205-210 (1993). In some situations it is desirable to provide the nucleic acid source with an agent which targets the target cells, such as an antibody specific for a surface membrane protein on the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. In liposomes, the decoy concentration in the lumen will generally be in the range of about 0.1 μM to 20 μM . For other techniques, the application rate

is determined empirically, using conventional techniques to determine desired ranges.

Usually, application of the subject therapeutics will be local, so as to be administered at the site of interest. Various techniques can be used for providing the subject compositions at the site of interest, such as injection, use of catheters, trocars, projectiles, pluronic gel, stents, sustained drug release polymers or other device which provides for internal access. Where an organ or tissue is accessible because of removal from the patient, such organ or tissue may be bathed in a medium containing the subject compositions, the subject compositions may be painted onto the organ, or may be applied in any convenient way. Systemic administration of the nucleic acid using lipofection, liposomes with tissue targeting (e.g. antibody) may also be employed.

The invention provides efficient methods of identifying pharmacological agents or lead compounds for agents active at the level of a TRADD or TRADD fragment modulatable cellular function, particularly a TRADD Death Domain mediated signal transduction, especially apoptosis. Generally, these screening methods involve assaying for compounds which interfere with a TRADD activity such as a TRADD Death Domain-TNF-R1 binding, etc. The methods are amenable to automated, cost-effective high throughput drug screening and have immediate application in a broad range of domestic and international pharmaceutical and biotechnology drug development programs. Target therapeutic indications are limited only in that the target cellular function be subject to modulation, usually inhibition, by disruption of the formation of a complex comprising a TRADD fragment and one or more natural TRADD fragment intracellular binding targets. Target indications may include infection, genetic disease, cell growth and regulatory dysfunction, such as neoplasia, inflammation, hypersensitivity, etc and other indication discussed herein.

A wide variety of assays for binding agents are provided including labelled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell based assays such as one, two and three hybrid screens, expression assays, etc. For example, three-hybrid screens are used to rapidly examine the effect of transfected nucleic acids, which may, for example, encode combinatorial peptide libraries or antisense molecules, on the intracellular binding

of TRADD fragments to specific intracellular targets. Convenient reagents for such assays (e.g. GAL4 fusion partners) are known in the art. An exemplary cell-based assay involves transfecting with a TRADD fragment a TNF-R1 expressing cell having a inducible reporter (e.g. gene encoding luciferase), the expression of which is operably linked to a gene expression regulatory region (e.g. NF- κ B binding site) activated, at least indirectly, by the TRADD fragment. Agents which modulate TRADD fragment mediated cell function are then detected through a change in the reporter. Preferred methods are rapid, in vitro, protein binding assays.

TRADD fragments used the methods are usually added in an isolated, partially pure or pure form and are typically recombinantly produced. The TRADD or TRADD fragment may be part of a fusion product with another peptide or polypeptide, e.g. a polypeptide that is capable of providing or enhancing protein-protein binding, sequence-specific nucleic acid binding or stability under assay conditions (e.g. a tag for detection or anchoring).

The assay mixtures comprise at least a portion of a natural intracellular TRADD fragment binding target such as the C-terminus TNF-R1 death domain. Where the natural intracellular TRADD fragment binding targets includes a nucleic acid, the mixture may comprise a nucleic acid comprising a sequence which shares sufficient sequence similarity with a gene or gene regulatory region to which the native (wild-type) TRADD fragment naturally binds to provide sequence-specific binding of the fragment. Such a nucleic acid may further comprise one or more sequences which facilitate the binding of a second protein or fragment thereof which cooperatively binds the nucleic acid with the TRADD fragment (i.e. at least one increases the affinity or specificity of the DNA binding of the other). While native binding targets may be used, it is frequently preferred to use portions (e.g. peptides, nucleic acid fragments) or analogs (i.e. agents which mimic the TRADD Death Domain binding properties of the natural binding target for the purposes of the assay) thereof so long as the portion provides binding affinity and avidity to the subject TRADD fragment conveniently measurable in the assay.

The assay mixture also comprises a candidate pharmacological agent. Generally a plurality of assay mixtures are run in parallel with different agent

concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the limits of assay detection. Candidate agents encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds. Small organic compounds have a molecular weight of more than 50 yet less than about 2,500, preferably less than about 1000, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with proteins and/or DNA, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups, more preferably at least three. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the forementioned functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives, structural analogs or combinations thereof, and the like. Where the agent is or is encoded by a transfected nucleic acid, said nucleic acid is typically DNA or RNA.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means. In addition, known pharmacological agents may be subject to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc., to produce structural analogs.

A variety of other reagents may also be included in the mixture. These include reagents like salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding and/or reduce non-specific or background interactions, etc. Also,

reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used.

The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the TRADD fragment specifically binds the cellular binding target, portion or analog. The mixture components can be added in any order that provides for the requisite bindings. Incubations may be performed at any temperature which facilitates optimal binding, typically between 4 and 40°C, more commonly between 15° and 40°C. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening, and are typically between .1 and 10 hours, preferably less than 5 hours, more preferably less than 2 hours.

After incubation, the presence or absence of specific binding between the TRADD fragment and one or more binding targets is detected by any convenient way. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate which may be any solid from which the unbound components may be conveniently separated. The solid substrate may be made of a wide variety of materials and in a wide variety of shapes, e.g. microtiter plate, microbead, dipstick, resin particle, etc. The substrate is chosen to maximize signal to noise ratios, primarily to minimize background binding, for ease of washing and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting reservoir such as a microtiter plate well, rinsing a bead (e.g. beads with iron cores may be readily isolated and washed using magnets), particle, chromatographic column or filter with a wash solution or solvent. Typically, the separation step will include an extended rinse or wash or a plurality of rinses or washes. For example, where the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific binding such as salts, buffer, detergent, nonspecific protein, etc. may exploit a polypeptide specific binding reagent such as an antibody or receptor specific to a ligand of the polypeptide.

Detection may be effected in any convenient way. For cell based assays such as one, two, and three hybrid screens, the transcript resulting from TRADD fragment-target binding usually encodes a directly or indirectly detectable product (e.g. galactosidase activity, luciferase activity, etc.). For cell-free binding assays, one of the components usually comprises or is coupled to a label. A wide variety of labels may be employed - essentially any label that provides for detection of bound protein. The label may provide for direct detection as radioactivity, luminescence, optical or electron density, etc. or indirect detection such as an epitope tag, an enzyme, etc. The label may be appended to the protein e.g. a phosphate group comprising a radioactive isotope of phosphorous, or incorporated into the protein structure, e.g. a methionine residue comprising a radioactive isotope of sulfur.

A variety of methods may be used to detect the label depending on the nature of the label and other assay components. For example, the label may be detected bound to the solid substrate or a portion of the bound complex containing the label may be separated from the solid substrate, and thereafter the label detected. Labels may be directly detected through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc. For example, in the case of radioactive labels, emissions may be detected directly, e.g. with particle counters or indirectly, e.g. with scintillation cocktails and counters. The methods are particularly suited to automated high throughput drug screening. Candidate agents shown to inhibit TRADD fragment - target binding provide valuable reagents to the biotechnology industries. In addition, the reagents find use in the pharmaceutical industries for animal and human trials; for example, the reagents may be derivatized and rescreened in in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development.

As previously described, the methods are particularly suited to automated high throughput drug screening. In a particular embodiment, the arm retrieves and transfers a microtiter plate to a liquid dispensing station where measured aliquots of each an incubation buffer and a solution comprising one or more candidate agents are deposited into each designated well. The arm then retrieves and transfers to and deposits in designated wells a measured aliquot of a solution

comprising a labeled transcription factor protein. After a first incubation period, the liquid dispensing station deposits in each designated well a measured aliquot of a biotinylated nucleic acid solution. The first and/or following second incubation may optionally occur after the arm transfers the plate to a shaker station. After a second incubation period, the arm transfers the microtiter plate to a wash station where the unbound contents of each well is aspirated and then the well repeatedly filled with a wash buffer and aspirated. Where the bound label is radioactive phosphorous, the arm retrieves and transfers the plate to the liquid dispensing station where a measured aliquot of a scintillation cocktail is deposited in each designated well. Thereafter, the amount of label retained in each designated well is quantified.

In more preferred embodiments, the liquid dispensing station and arm are capable of depositing aliquots in at least eight wells simultaneously and the wash station is capable of filling and aspirating ninety-six wells simultaneously. Preferred robots are capable of processing at least 640 and preferably at least about 1,280 candidate agents every 24 hours, e.g. in microtiter plates. Of course, useful agents are identified with a range of other assays (e.g. gel shifts, etc.) employing the subject TRADD fragments.

The following experiments and examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Here we describe the molecular cloning of a human TRADD that interacts specifically with the death domain of TNF-R1. We show that over-expression of this TRADD activates two major TNF signaling pathways, apoptosis and NF- κ B activation. Furthermore, the ICE inhibitor encoded by the cowpox virus *crmA* gene, which protects against apoptosis induced by TNF (Tewari and Dixit, 1995), also protects against TRADD-mediated cell death. However, *crmA* does not prevent TRADD-induced NF- κ B activation, demonstrating that the two signaling pathways emanating from this TRADD are distinct.

Isolation of cDNA Clones Encoding TNF-R1-Interacting Proteins: To identify proteins that directly interact with the intracellular region of TNF-R1 we

used the yeast two-hybrid system (Fields and Song, 1989). The yeast indicator strain HF7c was sequentially transformed with: i) an expression vector encoding the intracellular domain (amino acids 214-426) of human TNF-R1 fused to the yeast GAL4 DNA binding domain (GAL4bd-TNF-R1cd); and ii) GAL4 activation domain-tagged cDNA expression libraries prepared from HeLa and B cell mRNA. 48 positive clones, as determined by activation of *his* and *lacZ* reporter genes, were obtained from approximately 50 million transformants. 41 of these clones encoded portions of the cytoplasmic region of TNF-R1, indicating that the "death domain" (Tartaglia et al., 1993) of the receptor can self-associate. Similar findings using the yeast two-hybrid system were reported recently (Song et al., 1994; Boldin et al., 1995). DNA sequence analysis indicated that three [H10 (219 aa), B27 (194aa), B36 (118 aa)] of the remaining 7 clones were partial length cDNAs derived from the same gene. To isolate a full length cDNA we screened a human umbilical vein endothelial cell (HUVEC) cDNA library using the B27 cDNA as probe and obtained several cDNA clones of approximately 1.5 kb. DNA sequence analysis of these clones revealed an open reading frame (SEQUENCE ID NO:1) predicted to encode a protein of 312 amino acids (SEQUENCE ID NO:2) with a molecular mass of 34.2 kDa that we have designated TNF-R1 Associated Death Domain protein or TRADD. Database searches utilizing BLAST and FASTA programs failed to identify any proteins having significant sequence similarity to TRADD. A murine TRADD cDNA and encoded Death Domain is disclosed in SEQUENCE ID NO:3 and 4, respectively.

TRADD mRNA is Ubiquitously Expressed: Northern blot analysis indicated that low amounts of TRADD mRNA were expressed constitutively in all human tissues examined. This result is consistent with TRADD involvement in TNF-R1 signal transduction as TNF-R1 mRNA is also expressed ubiquitously (Loetscher et al., 1990; Schall et al., 1990; Lewis et al., 1991). The 1.4 kb size of the TRADD transcript confirms that the cDNA clones isolated from the HUVEC cDNA library represent full length copies of TRADD mRNA.

Detection of Endogenous TRADD: We prepared polyclonal antibodies against TRADD in order to examine the endogenously expressed protein. These antibodies were generated by expressing TRADD in *E. coli* as a GST fusion

protein and using the purified GST-TRADD chimera as immunogen. Rabbit anti-TRADD antiserum specifically recognized two proteins of approximately 34 kDa when tested by Western analysis using lysates prepared from 293 cells transiently transfected with a TRADD expression vector. The weak upper band of the doublet may be a post-translationally modified TRADD. Protein bands of the same size, corresponding to endogenous TRADD, could be detected in lysates from ECV304, HeLa, and HepG2 cells prepared using 50-fold more cells. These results indicate that the TRADD cDNA clone encodes a full length copy of the TRADD protein.

TRADD Specifically Interacts with TNF-R1 and Self-Associates: To confirm that full length TRADD interacts specifically with TNF-R1, several additional two-hybrid assays were performed. A protein consisting of the GAL4 activation domain fused to full length TRADD (GAL4ad-TRADD) was co-expressed with the GAL4bd-TNF-R1_{icd} fusion protein in yeast strain SFY526. The GAL4ad-TRADD chimera interacted with the GAL4bd-TNF-R1_{icd} fusion protein, but not with the GAL4 DNA binding domain alone. We also tested the ability of the GAL4ad-TRADD fusion protein to interact with receptors that are related to TNF-R1 either in terms of their structure (TNF-R2 and Fas antigen) or the signals they generate (Fas antigen and the type I IL-1 receptor [IL1-R1]). However, GAL4ad-TRADD failed to interact with the cytoplasmic domains of TNF-R2, IL1-R1, or Fas antigen expressed as GAL4bd chimeras.

To further examine the specificity of the interaction between TRADD and TNF-R1, the GAL4bd was fused to two different C-terminal deletion mutants of TNF-R1_{icd} (Tartaglia et al., 1993b) as well as to the cytoplasmic domain of murine TNF-R1. GAL4ad-TRADD interacted strongly with an active receptor mutant (D413-426) lacking 14 amino acids, yet interacted weakly with an inactive mutant (D407-426) lacking 20 amino acids. These results indicate that amino acids 407-412 of TNF-R1, which are required for the signaling of cytotoxicity, antiviral activity (Tartaglia et al., 1993b) and NF- κ B activation, contribute to, but are not required for its TRADD interaction. The interaction of TRADD with mouse TNF-R1 in this assay system was specific, but weaker than with the homologous human TNF-R1.

We next performed *in vitro* biochemical assays to confirm the specific interaction of TNF-R1 with TRADD observed in the two-hybrid system. GST fusion proteins containing the cytoplasmic domains of TNF-R1, TNF-R2, IL1-R1 and Fas antigen were expressed in *E. coli* and purified. These fusion proteins were tested for interaction with ³⁵S-labeled TRADD prepared by *in vitro* transcription and translation. TRADD associated only with the GST-TNF-R1 fusion protein. Furthermore, TRADD did not associate with a GST-TNF-R1(-20) fusion protein derived from the inactive TNF-R1 mutant D407-426.

To determine whether TRADD exists as a monomer we prepared a "reverse" two-hybrid construct in which TRADD was fused to the GAL4bd. The results of a yeast cotransformation experiment using this construct and the GAL4ad-TRADD construct indicated that these two hybrid proteins interact with each other. We conclude that TRADD is an oligomeric protein.

TRADD: TNF-R1 Interaction in Human Cells: Extensive mutational analysis of TNF-R1 has led to the identification of several residues in its "death" domain that are important for the generation of a cytotoxic response (Tartaglia et al., 1993b). To determine whether a correlation exists between the ability of a TNF-R1 mutant to deliver a cytotoxic signal and to interact with TRADD, we utilized a mammalian cell co-immunoprecipitation assay. An expression vector that directs the synthesis of TRADD containing an N-terminal myc epitope tag was cotransfected with various TNF-R1 constructs into human embryonic kidney 293 cells. Cell extracts were immunoprecipitated using polyclonal antibodies against the extracellular domain of TNF-R1 and coprecipitating TRADD was detected by western blotting with an anti-myc monoclonal antibody. As determined by this assay, TRADD specifically associates with TNF-R1. Five different deletion and point mutants of TNF-R1 were also examined by this method. The two active mutants (D413-426 and D212-308) were able to coprecipitate TRADD, whereas two of the three inactive mutants (D212-340 and K343,F345,R347) failed to do so. The third inactive mutant (D407-426) coprecipitated TRADD weakly in some experiments and not at all in others. Accordingly, it appears that residues throughout the ~80 amino acid death domain of TNF-R1 are critical for TRADD interaction.

Overexpression of TRADD Induces Apoptosis: One of the major activities signaled by TNF through TNF-R1 is programmed cell death or apoptosis. To investigate a possible role for TRADD in TNF-mediated apoptosis, 293 cells were transiently transfected with a TRADD expression vector and examined by phase contrast microscopy 24 hours later. 293 cells that overexpressed TRADD had obvious morphological differences from those transfected with a control vector. The TRADD-expressing cells displayed the typical characteristics of adherent cells undergoing apoptosis (reviewed in Tomei and Cope, 1991). Shortly following transfection these cells became rounded, condensed (average diameter ~ 15 μ m) and began to detach from the dish. Cells transfected with a control vector remained flat with an average length of ~40-50 μ m.

One biochemical hallmark of apoptosis is the internucleosomal fragmentation of nuclear DNA which results in a distinct laddering pattern when analyzed by agarose gel electrophoresis (Tomei and Cope, 1991). We examined nuclear DNA from 293 cells transfected with either a control vector or with the TRADD expression vector. DNA isolated from TRADD-expressing cells displayed a profile characteristic of apoptosis and closely resembled the DNA from untransfected 293 cells that were treated with TNF. A small amount of DNA fragmentation was also observed in the vector control which we attribute to the transfection procedure.

It was recently shown (Tewari and Dixit, 1995) that TNF-induced apoptosis can be inhibited by the ICE-specific serpin inhibitor encoded by the cowpox *crmA* gene (Ray et al., 1992). This led us to examine the effects of *crmA* protein and other known inhibitors of apoptosis (Bcl-2 and adenovirus 19K E1B proteins) on TRADD-induced cell death. The appearance of 293 cells cotransfected with expression vectors encoding both TRADD and *crmA* was indistinguishable from cells transfected with a control vector alone. Conversely, co-expression of either the *Bcl-2* or *E1B* gene product did not counteract the apoptotic effect of TRADD expression on 293 cells. Furthermore, *crmA* co-expression also blocked the generation of TRADD-induced DNA laddering. These results are consistent with the interpretation that TRADD-induced apoptosis involves activation of ICE or a related protease.

To ensure that the induction of apoptosis by TRADD was not a peculiarity of 293 cells, we also examined the effects of TRADD overexpression on HeLa, HepG2, and murine NIH-3T3 cells. In these cases, low transient transfection efficiency precluded use of the assays described above for 293 cells. Instead, a b-galactosidase cotransfection assay (Kumar et al., 1994) was used to examine cell viability. Cells were transiently transfected with a b-galactosidase expression plasmid and the various expression vectors described above. 36 hours later cells were stained with X-gal and positive blue cells visualized and counted. In all cell lines a dramatic (~100-fold) reduction in the number of b-galactosidase-positive cells was observed for the TRADD vector compared to the control vector. When crmA and TRADD were coexpressed, the crmA effect was obvious and the number of blue HeLa and NIH-3T3 cells was the same as in the vector controls. Co-expression of crmA protected about one-third of transfected HepG2 cells from TRADD-induced cell death. As was seen in 293 cells, neither Bcl-2 nor E1B expression exerted a protective effect on TRADD-mediated apoptosis in HeLa or NIH-3T3 cells. Bcl-2 did provide partial protection for HeLa cells from the effect of TRADD overexpression.

TRADD Overexpression Activates NF- κ B: Another important activity of TNF signaled by TNF-R1 is activation of the transcription factor NF- κ B. To examine a possible role for TRADD in this process we performed electrophoretic mobility shift assays (EMSAs) on nuclear extracts from 293 cells 24 hours after transient transfection with the TRADD expression vector. TRADD-expressing 293 cells were found to contain a significant amount of activated NF- κ B even in the absence of exogenous TNF. In contrast, specific NF- κ B complexes were detected only after TNF treatment in 293 cells transfected with an empty expression vector. Supershift experiments performed with antibodies demonstrate that the major component of the activated NF- κ B complex appears to be the p65:p50 heterodimer.

Dose response experiments were performed to determine if TRADD expression might lead to activation of a NF- κ B-dependent reporter gene. An E-selectin-luciferase reporter construct (Schindler and Baichwal, 1994) was cotransfected with increasing amounts of the TRADD expression vector into 293 cells. TRADD expression potently activated the reporter gene with maximal

luciferase activity (approx. 400-fold induction) occurring at a 0.32 mg dose of the TRADD expression vector. These levels of reporter gene induction are greater than the ~20-fold induction observed when 293 cells are treated with TNF alone. Further increases in TRADD vector resulted in diminished levels of reporter activity, probably due to induction of cell death. The observed luciferase induction was dependent on NF- κ B activation since TRADD expression failed to activate a control reporter construct in which the NF- κ B site in the E-selectin promoter was mutated.

CrmA does not block TRADD-induced NF- κ B Activation: Since crmA is a potent inhibitor of apoptosis induced by either TNF treatment (Tewari and Dixit, 1995) or TRADD expression, we were interested in examining its effect on NF- κ B activation. To do this, 293 cells were cotransfected with the E-selectin reporter construct and expression vectors for crmA, TRADD, or both. CrmA expression had little or no effect on TRADD-induced NF- κ B activation in 293 cells as determined by either EMSA or the luciferase reporter gene assay.

HeLa and HepG2 cells were also examined for NF- κ B activation following transient transfection with the TRADD expression vector alone. In most experiments no activation was seen in these cell lines, a result potentially attributable to rapid induction of cell death. To determine whether NF- κ B could be activated by TRADD if cell death were inhibited, these cell lines were cotransfected with crmA and TRADD expression vectors. While crmA expression alone had no effect, substantial activation of NF- κ B was observed in the crmA/TRADD cotransfection experiments. These results demonstrate an inherent ability of TRADD to activate NF- κ B, which can be more readily observed if the death pathway is blockaded by crmA expression.

Deletion Mutagenesis of TRADD: The experiments described thus far have identified four distinct properties of TRADD: (i) interaction with TNF-R1; (ii) self-association; (iii) induction of apoptosis; and (iv) activation of NF- κ B. To ascertain whether these properties reside in common or distinct domains of TRADD, we constructed myc-tagged expression vectors for a series of N- and C-terminal deletion mutants. The ability of each mutant to induce apoptosis was determined in the 293 transient assay described above. A TRADD mutant (Δ 1-194) containing only 118 C-terminal amino acids was able to trigger cell death,

whereas a mutant ($\Delta 1-204$) ten amino acids shorter did not. Deleting from the C-terminus, a mutant ($\Delta 301-312$) lacking only 12 residues was inactive, but a mutant ($\Delta 306-312$) lacking seven amino acids retained the ability to induce apoptosis of 293 cells. This analysis localized the apoptosis activation function (death domain) of TRADD to a 111 residue region extending from amino acid 195 to 305. NF- κ B activation for each TRADD mutant was determined in the NF- κ B reporter co-transfection assay. By this analysis the region of TRADD required for NF- κ B activation was strictly concordant with that required for apoptosis.

The TRADD deletion mutants were assayed for association with TNF-R1 by measuring the interaction of 35 S-labeled in vitro translated mutants with a GST-TNF-R1 fusion protein. Two mutants ($\Delta 306-312$ and $\Delta 1-194$) bound as well as wild-type TRADD to TNF-R1. These same two mutants were biologically active as determined by the apoptosis and NF- κ B activation assays. TRADD mutants that were inactive in these biological assays bound TNF-R1 poorly, or not at all.

The ability of the TRADD deletion mutants to self-oligomerize was assessed by binding experiments between a GST-TRADD fusion protein and the in vitro translated mutants. The same mutants that interacted with GST-TNF-R1 were able to bind GST-TRADD, although by this assay self-association was much weaker than interaction with TNF-R1. The one difference observed was that the biologically inactive $\Delta 301-312$ mutant, which does not interact with TNF-R1, was still able to self-associate. These results demonstrate that a 111 amino acid domain (aa 195-305) of TRADD is capable of oligomerization, TNF-R1 interaction, stimulation of programmed cell death and NF- κ B activation.

Death Domains of TRADD and TNF-R1 Share Sequence Similarity:
Database screens failed to identify any proteins bearing significant similarity to the primary amino acid sequence of TRADD. However, since the 111 amino acid death domain of TRADD shares many properties with the ~ 80 amino acid death domain of TNF-R1, these two sequences were directly compared. Alignment of TRADD residues 196-302 relative to residues 319-425 of TNF-R1 results in 25 identities over 107 amino acids (23%). The most obvious sequence similarity was found in the stretch of 68 amino acids (TRADD residues 222-289 and TNF-R1 residues 345-412). If a single gap is introduced in both sequences

(after TRADD 235 and after TNF-R1 364), 22 identities (32%) and 21 conservative changes are found. Whereas the majority of the identities are leucines and arginines, three observations indicate that the sequence similarity may be functionally significant: (i) six amino acids have been identified in the death domain of TNF-R1 that, when mutated to alanine, abolish signaling (Tartaglia et al., 1993b). Five of these six amino acids, which extend to both ends of the aligned sequence, are identical or highly conserved in TRADD; (ii) the sequence similarity between TRADD and TNF-R1 over this region is roughly the same as that between the functionally similar death domains of TNF-R1 and Fas antigen; and (iii) TRADD and Fas antigen, which appear not to interact with each other, share only 9 identities (13%) over these 68 residues.

Reagents and Cell Lines: Recombinant human TNF (specific activity $> 10^7$ units/mg) was provided by Genentech, Inc. The rabbit anti-TNF-R1 polyclonal antibody was described previously (Tartaglia et al., 1991). The rabbit anti-TRADD antiserum was raised against a GST-TRADD fusion protein by BABCO (Richmond, CA). Rabbit anti-p50 and anti-p65 polyclonal antibodies were purchased from Santa Cruz Biotechnology. The HtTA-1 (HeLa expressing a tetracycline-controlled transactivator; Hermann Bujard), 293 (Robert Tjian), HepG2 (American Type Culture Collection [ATCC]), ECV304 (ATCC), and NIH-3T3 (Steve McKnight) cell lines were obtained from the indicated sources.

Expression Vectors: The TRADD cDNA was cloned as a 1.4 kb EcoRI fragment into pRK5 under the transcriptional control of the cytomegalovirus (CMV) immediate early promoter-enhancer (Schall et al., 1990). The resulting plasmid pRK-TRADD was used for mammalian cell expression and for in vitro transcription and translation using the SP6 promoter. Myc epitope-tag constructs were made by replacing the eight N-terminal codons of TRADD with DNA encoding the sequence M-A-S-M-E-Q-K-L-I-S-E-E-D-L (SEQUENCE ID NO:5). C-terminal deletion mutants of TRADD were generated by replacement of sequences between the XhoI site in TRADD and the HindIII site in pRK5 with synthetic DNA containing the appropriate coding sequence and in-frame stop codons. N-terminal deletion constructs of TRADD were generated by PCR and contained the N-terminal myc epitope-tag sequence. The various mutant TNF-R1 expression vectors were described previously (Tartaglia et al., 1993b). A plasmid

containing the cowpox virus *crmA* gene is described in Pickup et al., 1986. A 1.0 kb *crmA* fragment was generated by PCR and inserted into the pRK5 vector to give the plasmid pRK-*crmA*. The Bcl-2 expression vector pSFFV-Bcl-2 was based on the long terminal repeat of the splenic focus-forming virus. The NF- κ B-luciferase reporter plasmid pELAM-luc, containing E-selectin promoter sequences from position -730 to +52 is described in Schindler and Baichwal, 1994.

Yeast Two-Hybrid Cloning: DNA encoding the intracellular domain (amino acids 214-426) of TNF-R1 was cloned into the yeast GAL4 DNA binding domain vector pGBT9. The resulting plasmid pGAL4bd-TNF-R1cd used as bait in two-hybrid screens of HeLa and B cell cDNA libraries (Clontech) following the Matchmaker Two-Hybrid System Protocol (Clontech). Briefly, the *S. cerevisiae* indicator strain HF7c was transformed sequentially with the bait plasmid and a cDNA library. Positive yeast clones were selected by prototrophy for histidine and expression of b-galactosidase. Yeast DNA was recovered and transformed into *E. coli*. Plasmids containing cDNA clones were identified by restriction mapping and further characterized by DNA sequencing. Subsequent two-hybrid interaction analyses were carried out by cotransformation of plasmids containing the GAL4 DNA binding (pGBT9) and activation (pGAD424) domains into *S. cerevisiae* strain SFY526. Assays for b-galactosidase activity were performed using CPRG as substrate (Iwabuchi et al., 1993).

cDNA Cloning and Northern Hybridization: The cDNA insert of approximately 1 kb from two-hybrid clone B27 was used as probe to screen human HeLa and umbilical vein endothelial cell (HUVEC) cDNA libraries in lgt11 (provided by Dr. Zhaodan Cao; complexity of $> 2 \times 10^6$ clones each) by standard methods (Sambrook et al., 1989). Two independent positive clones were obtained from each library. Following subcloning into pBluescript KS (Stratagene) DNA sequencing was performed on an ABI model 373A automated DNA sequencer using the Prism Dye Terminator Cycle sequencing kit (Applied Biosystems). Northern analysis of the human multiple tissue blot (Clontech) was performed according to the manufacturer's instructions using an ~400bp EcoRI-NarI fragment from the 5' end of TRADD cDNA as probe.

Cell Culture, Transfections and Reporter Assays: 293 and NIH-3T3 cells were maintained in high glucose DMEM medium containing 10% FCS, 100

mg/ml penicillin G and 100mg/ml streptomycin (Gibco). HtTA-1 (HeLa) cells were grown in the same medium containing 400 mg/ml G418. HepG2 cells were maintained in DMEM/F12 (1:1) medium with the same additives. For reporter assays, co-immunoprecipitations, and cell killing assays, $\sim 2 \times 10^5$ cells/well were seeded on 6-well (35 mm) dishes and grown in 5% CO₂ at 37°C. The following day, cells were transfected by the calcium phosphate precipitation method (Ausubel et al., 1994). The control vector pRK5 was used as carrier DNA so that all transfections in a given experiment contained equal amounts of total DNA. After an incubation of 24-36 hours, cells were washed twice with PBS and then lysed with 200 μ l lysis buffer (25 mM Tris-phosphate pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% triton X-100). 20 μ l aliquots of cell lysates were mixed with 100 μ l of luciferase assay reagent (Promega) and the luciferase activity determined using a Model 20e luminometer (Turner Designs). b-galactosidase activity was determined in a mixture containing 10 μ l of cell lysate, 10 μ l of 50 mM CPRG (chlorophenol red b-D-galactopyranoside) and 80 μ l of Z buffer (60 mM Na₂HPO₄, 10 mM KCl, 1 mM b-mercaptoethanol, pH 7.0). Samples were incubated at 37°C until red color developed and absorbance determined at 574 nm. These values were used to normalize transfection efficiencies. For DNA laddering and EMSA experiments large scale transfections were performed using 100 mm dishes seeded with $\sim 10^6$ cells. 24-36 hours after transfection, DNA or nuclear extracts were prepared as described below.

Co-immunoprecipitations and Western Analysis: Western analysis to detect TRADD was performed with the anti-TRADD antiserum and horseradish peroxidase-coupled goat anti-rabbit IgG (Amersham) using enhanced chemiluminescence according to the manufacturer's protocol. For immunoprecipitation assays, 50 μ l aliquots of lysates from transfected cells were incubated with 1 μ l of the anti-TNF-R1 antibody and 450 μ l E1A buffer (50 mM Hepes pH 7.6, 250 mM NaCl, 0.1% NP-40, 5 mM EDTA). The mixture was incubated at 4°C for 1 hour, then mixed with 20 μ l of a 1:1 slurry of protein A sepharose (Pharmacia) and incubated for another hour. The beads were washed twice with 1 ml E1A buffer, twice with 1 ml high salt (1 M NaCl) E1A buffer, and twice again with E1A buffer. The precipitates were fractionated

on 10% SDS-PAGE and then transferred electrophoretically to Immobilon-P membrane (Millipore). The blot was then subjected to Western analysis with anti-myc monoclonal antibody and horseradish peroxidase-coupled rabbit anti-mouse Ig (Amersham) as described above.

Generation of GST Fusion Proteins and in Vitro Binding Assays: TRADD and the cytoplasmic regions of TNF-R1, TNF-R1(-20), Fas antigen, IL1-R1, TNF-R2 were expressed individually as GST (glutathione-S-transferase) fusion proteins using pGEX vectors (Pharmacia). Expression and purification of the GST fusion proteins were performed as described (Smith and Johnson, 1988). ³⁵S-labeled proteins were generated using the TNT SP6 Coupled Reticulocyte Lysate System (Promega) and the various TRADD expression constructs in pRK5. For each in vitro binding assay, 10ml of glutathione sepharose beads (Pharmacia) bound to the appropriate GST fusion protein (~5mg) was incubated with ³⁵S-labeled polypeptides (equivalent cpm as determined by phosphorimager) in 1 ml of E1A buffer at 4°C for one hour. The beads were then washed six times with E1A buffer. Proteins on the beads were fractionated by SDS-PAGE and exposed to Kodak X-ray film following drying of the gel.

Apoptosis Assays: DNA fragmentation assays were performed essentially as described (Hermann et al., 1994). Briefly, approximately 10⁷ transfected or nontransfected cells were washed with PBS, pelleted and lysed in 20 mM EDTA, 50 mM Tris-HCl (pH 7.5) containing 1% NP-40. After a 5 min centrifugation at 1600 x g, the supernatant was brought to 1% SDS, and treated 2 hr with 5 mg/ml RNase A at 56°C and 2hr with 2.5 mg/ml proteinase K at 37°C. The mixture was extracted with phenol/ chloroform, DNA was ethanol precipitated and 150 ng DNA aliquots were fractionated by electrophoresis in a 1.6% agarose gel.

β-galactosidase cotransfection assays for determination of cell death were performed as described by Kumar et al. (1994). Transfected cells were washed with PBS, fixed at 4°C for 5 min in PBS containing 2% paraformaldehyde, 0.2% glutaraldehyde, washed again with PBS, and stained for at least 3 hours with PBS containing 1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl₂, 0.02% NP-40, 0.01% SDS. Cells were observed microscopically and the number of blue cells per 35 mm well was determined by

counting. At least three independent transfections were performed for each set of conditions.

Electrophoretic Mobility Shift Assays: Nuclear extracts were prepared as described by Osborn et al. (1989). Double-stranded deoxyoligonucleotides containing an NF- κ B binding site were 32 P-labeled using polynucleotide kinase. Each gel shift assay was performed in a 30 ml reaction mixture, which contained 10 mg nuclear extracts, 0.4 ng of radiolabeled oligonucleotide probe, 1 mg of sonicated E. coli DNA, 6 ml of 5 X EMSA buffer (100 mM Hepes pH 7.6, 250 mM KCl, 5 mM DTT, 5 mM EDTA, 25% glycerol), and where necessary, 20 mg of cold competitor oligonucleotides. Mixtures were incubated at room temperature for 10 minutes and then subjected to electrophoretic fractionation on a 5% polyacrymide gel at 4°C.

Cited References: Ausubel et al. (1994) *Current Protocols in Molecular Biology* (New York: Greene Publishing Associates/Wiley & Sons, Inc.); Beg et al. (1993) *Genes Dev.* 7:2064-2070; Beg et al. (1993) *Molec. and Cell. Biol.* 1993:3301-3310; Boldin et al. (1995) *J. Biol. Chem.* 270:387-391; Darnell et al. (1994) *Science* 264:1415-1421; Englemann et al. (1990) *J. Biol. Chem.* 265:14497-14504; Erickson et al. (1994) *Nature* 372:560-563; Espevik et al. (1990) *J. Exp. Med.* 171:415-426; Fantl et al. (1993) *Ann. Rev. Biochem.* 62:453-482; Fields and Song (1989) *Nature* 340:245-246; Gagliardini et al. (1994) *Science* 263:826-828; Gehr et al. (1992) *J. Immunol.* 149:911-917; Goodwin et al. (1991) *Mol. Cell. Biol.* 11:3020-3026; Hermann et al. (1994) *Nucl. Acids Res.* 22:5506-5507; Hu et al. (1994) *J. Biol. Chem.* 269:30069-30072; Itoh et al. (1993) *J. Biol. Chem.* 268:10932-10937; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; Jacobsen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:10695-10699; Kishimoto et al. (1994) *Cell* 76:253-262; Kruppa (1992) *J. Immunol.* 148:3152-3157; Kumar et al. (1994) *Genes & Devel.* 8:1613-1626; Lægreid et al. (1994) *J. Biol. Chem.* 269:7785-7791; Lewis et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:2830-2834; Liou and Baltimore (1993) *Curr. Opin. Cell Biol.* 5:477-487; Loetscher (1990) *Cell* 61:351-359; Miura et al. (1993) *Cell* 75:656-660; Osborn et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2336-2340; Palombella et al. (1994) *Cell* 78:773-785; Pfeffer et al. (1993) *Cell* 73:457 - 467; Pickup et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:7698-7702; Ray et al. (1992) *Cell* 69:587-604; Rothe et al. (1992) *Immunol. Res.* 11:81-90; Rothe et al. (1993) *Nature* 364:798-802;

Rothe et al. (1994) *Cell* 78:681-692; Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, Second Edition (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Schall et al. (1990) *Cell* 61:361-370; Schindler and Baichwal (1994) *Mol. Cell. Biol.* 14:5820-5831; Schlessinger and Ullrich (1992) *Neuron* 9:383-391; Schulze-Osthoff et al. (1994) *EMBO J.* 13:4587-4596; Smith et al. (1990) *Science* 248:1019-1023; Smith et al. (1994) *Cell* 76:959-962; Smith and Johnson (1988) *Gene* 67:31-40; Song et al. (1994) *J. Biol. Chem.* 269:22492-22495; Tartaglia et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:9292-9296; Tartaglia and Goeddel (1992) *Immunol. Today* 13:151-153; Tartaglia et al. (1993a) *J. Immunol.* 151:4637-4641; Tartaglia et al. (1993b) *Cell* 74:845-853; Tewari and Dixit (1995) *J. Biol. Chem.* 270:3255-3260; Thornberry et al. (1992) *Nature* 356:768-774; Tomei and Cope (1991) *Current Communications in Cell & Molecular Biology* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); VanArsdale and Ware (1994) *J. Immunol.* 153:3043-3050; Vandenabeele et al. (1992) *J. Exp. Med.* 176:1015-1024; Wiegmann et al. (1994) *Cell* 78:1005-1015; Wong and Goeddel (1994) *J. Immunol.* 152:1751-1755; Wong et al. (1992) *J. Immunol.* 149:3550-3553; and Yuan et al. (1993) *Cell* 75:641-652.

EXAMPLES

1. Protocol for TRADD - TNF-R1 binding assay.

A. Reagents:

- Neutralite Avidin: 20 µg/ml in PBS.
- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hr, RT.
- Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 0.25 mM EDTA, 1% glycerol, 0.5 % NP-40, 50 mM BME, 1 mg/ml BSA, cocktail of protease inhibitors.
- ³³P TRADD 10x stock: 10⁻⁸ - 10⁻⁶ M "cold" TRADD supplemented with 200,000-250,000 cpm of labeled TRADD (Beckman counter). Place in the 4°C microfridge during screening.
- Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVO₃ (Sigma # S-6508) in 10 ml of PBS.

- TNF-R1 Death Domain: 10^{-8} - 10^{-5} M biotinylated TNF-R1 Death Domain (residues 327-412) in PBS.

B. Preparation of assay plates:

- Coat with 120 μ l of stock N-Avidin per well overnight at 4°C.
- Wash 2X with 200 μ l PBS.
- Block with 150 μ l of blocking buffer.
- Wash 2X with 200 μ l PBS.

C. Assay:

- Add 40 μ l assay buffer/well.
- Add 10 μ l compound or extract.
- Add 10 μ l 33 P-TRADD (20,000-25,000 cpm/0.1-10 pmoles/well = 10^{-9} - 10^{-7}

M final concentration).

- Shake at 25C for 15 min.
- Incubate additional 45 min. at 25C.
- Add 40 μ l TNF-R1 Death Domain (0.1-10 pmoles/40 μ l in assay buffer)
- Incubate 1 hr at RT.
- Stop the reaction by washing 4X with 200 μ l PBS.
- Add 150 μ l scintillation cocktail.
- Count in Topcount.

D. Controls for all assays (located on each plate):

- a. Non-specific binding (no TNF-R1 Death Domain added)
- b. Soluble (non-biotinylated TNF-R1 Death Domain) at 80%

inhibition.

1. Protocol for TRADD - TRADD binding assay.

A. Reagents:

- TRADD: 20 μ g/ml in PBS.
- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hr, RT.
- Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 0.25 mM EDTA, 1% glycerol, 0.5 % NP-40, 50 mM BME, 1 mg/ml BSA, cocktail of protease inhibitors.

- ^{32}P TRADD 10x stock: 10^{-8} - 10^{-6} M "cold" TRADD supplemented with 200,000-250,000 cpm of labeled TRADD (Beckman counter). Place in the 4°C microfridge during screening.

- Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVO_3 (Sigma # S-6508) in 10 ml of PBS.

B. Preparation of assay plates:

- Coat with 120 μl of stock TRADD per well overnight at 4°C .
- Wash 2X with 200 μl PBS.
- Block with 150 μl of blocking buffer.
- Wash 2X with 200 μl PBS.

C. Assay:

- Add 80 μl assay buffer/well.
 - Add 10 μl compound or extract.
 - Add 10 μl ^{32}P -TRADD (20,000-25,000 cpm/0.3 pmoles/well = 3×10^{-9} M final concentration).
 - Shake at 25°C for 15 min.
 - Incubate additional 45 min. at 25°C .
 - Stop the reaction by washing 4X with 200 μl PBS.
 - Add 150 μl scintillation cocktail.
 - Count in Topcount.
- D. Controls for all assays (located on each plate):
- a. Non-specific binding (no stock TRADD added)
 - b. cold TRADD at 80% inhibition.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings

of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: TULARIK, INC.
- (ii) TITLE OF INVENTION: INTRACELLULAR SIGNALING PROTEINS AND METHODS OF USE
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
 - (B) STREET: 4 Embarcadero Center, Suite 3400
 - (C) CITY: San Francisco
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94111-4187
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US96/03591
 - (B) FILING DATE: MAR 14 1996
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US Serial No. 08/414,625
 - (B) FILING DATE: MAR 31 1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Brezner, David J.
 - (B) REGISTRATION NUMBER: 24,447
 - (C) REFERENCE/DOCKET NUMBER: FP-60916/DJB
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 781-1989
 - (B) TELEFAX: (415) 398-3249
 - (C) TELEX: 910 277299

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1441 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 49..987

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

CTGGCGGGCG TGGGAACCCA GGCCCCGCCG AGGCGGCCAG GAGGTGAG ATG GCA GCT      57
                                         Met Ala Ala
                                         1
GGG CAA AAT GGG CAC GAA GAG TGG GTG GGC AGC GCA TAC CTG TTT GTG      105
Gly Gln Asn Gly His Glu Glu Trp Val Gly Ser Ala Tyr Leu Phe Val
      5              10              15

```

GAG Glu 20	TCC Ser	TCG Ser	CTG Leu	GAC Asp	AAG Lys 25	GTG Val	GTC Val	CTG Leu	TCG Ser	GAT Asp 30	GCC Ala	TAC Tyr	GCG Ala	CAC His	CCC Pro 35	153
CAG Gln	CAG Gln	AAG Lys	GTG Val	GCA Ala 40	GTG Val	TAC Tyr	AGG Arg	GCT Ala	CTG Leu 45	CAG Gln	GCT Ala	GCC Ala	TTG Leu	GCA Ala 50	GAG Glu	201
AGC Ser	GGC Gly	GGG Gly	AGC Ser 55	CCG Pro	GAC Asp	GTG Val	CTG Leu	CAG Gln 60	ATG Met	CTG Leu	AAG Lys	ATC Ile	CAC His 65	CGC Arg	AGC Ser	249
GAC Asp	CCG Pro	CAG Gln 70	CTG Leu	ATC Ile	GTG Val	CAG Gln 75	CTG Leu	CGA Arg	TTC Phe	TGC Cys	GGG Gly	CGG Arg 80	CAG Gln	CCC Pro	TGT Cys	297
GGC Gly 85	CGC Arg	TTC Phe	CTC Leu	CGC Arg	GCC Ala	TAC Tyr 90	CGC Arg	GAG Glu	GGG Gly	GCG Ala 95	CTG Leu	CGC Arg	GCC Ala	GCG Ala	CTG Leu	345
CAG Gln 100	AGG Arg	AGC Ser	CTG Leu	GCG Ala	GCC Ala 105	CTC Leu	GCC Ala	CAG Gln 110	CAC His	TCG Ser	GTG Val	CCG Pro	CTG Leu 115	CAA Gln		393
CTG Leu	GAG Glu	CTG Leu	CGC Arg	GCC Ala 120	GGC Gly	GCC Ala	GAG Glu	CGG Arg 125	CTG Leu	GAC Asp	GCT Ala	TTG Leu	CTG Leu	GCG Ala 130	GAC Asp	441
GAG Glu	GAG Glu	CGC Arg	TGT Cys 135	TTG Leu	AGT Ser	TGC Cys	ATC Ile	CTA Leu 140	GCC Ala	CAG Gln	CAG Gln	CCC Pro	GAC Asp 145	CGG Arg	CTC Leu	489
CGG Arg	GAT Asp	GAA Glu 150	GAA Glu	CTG Leu	GCT Ala	GAG Glu	CTG Leu 155	GAG Glu	GAT Asp	GCG Ala	CTG Leu	CGA Arg 160	AAT Asn	CTG Leu	AAG Lys	537
TGC Cys 165	GGC Gly	TCG Ser	GGG Gly	GCC Ala	CGG Arg	GGT Gly 170	GGC Gly	GAC Asp	GGG Gly	GAG Glu	GTC Val 175	GCT Ala	TCG Ser	GCC Ala	CCC Pro	585
TTG Leu 180	CAG Gln	CCC Pro	CCG Pro	GTG Val	CCC Pro 185	TCT Ser	CTG Leu	TCG Ser	GAG Glu	GTG Val 190	AAG Lys	CCG Pro	CCG Pro	CCG Pro	CCG Pro 195	633
CCG Pro	CCA Pro	CCT Pro	GCC Ala	CAG Gln	ACT Thr	TTT Phe	CTG Leu	TTC Phe	CAG Gln	GGT Gly	CAG Gln	CCT Pro	GTA Val	GTG Val 210	AAT Asn	681
CGG Arg	CCG Pro	CTG Leu	AGC Ser 215	CTG Leu	AAG Lys	GAC Asp	CAA Gln 220	CAG Gln	ACG Thr	TTC Phe	GCG Ala	CGC Arg	TCT Ser 225	GTG Val	GGT Gly	729
CTC Leu	AAA Lys	TGG Trp 230	CGC Arg	AAG Lys	GTG Val	GGG Gly	CGC Arg 235	TCA Ser	CTG Leu	CAG Gln	CGA Arg	GGC Gly 240	TGC Cys	CGG Arg	GCG Ala	777
CTG Leu 245	CGG Arg	GAC Asp	CCG Pro	GCG Ala	CTG Leu	GAC Asp 250	TCG Ser	CTG Leu	GCC Ala	TAC Tyr	GAG Glu 255	TAC Tyr	GAG Glu	CGC Arg	GAG Glu	825
GGA Gly 260	CTG Leu	TAC Tyr	GAG Glu	CAG Gln	GCC Ala 265	TTC Phe	CAG Gln	CTG Leu	CTG Leu	CGG Arg 270	CGC Arg	TTC Phe	GTG Val	CAG Gln	GCC Ala 275	873
GAG Glu	GGC Gly	CGC Arg	CGC Arg	GCC Ala 280	ACG Thr	CTG Leu	CAG Gln	CGC Arg	CTG Leu 285	GTG Val	GAG Glu	GCA Ala	CTC Leu	GAG Glu	GAG Glu	921

(2) INFORMATION FOR SEO ID NO:2:

(A) LENGTH: 312 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

33

Ser Ala Pro Leu Gln Pro Pro Val Pro Ser Leu Ser Glu Val Lys Pro
 180 185 190

Pro Pro Pro Pro Pro Pro Ala Gln Thr Phe Leu Phe Gln Gly Gln Pro
 195 200 205

Val Val Asn Arg Pro Leu Ser Leu Lys Asp Gln Gln Thr Phe Ala Arg
 210 215 220

Ser Val Gly Leu Lys Trp Arg Lys Val Gly Arg Ser Leu Gln Arg Gly
 225 230 235 240

Cys Arg Ala Leu Arg Asp Pro Ala Leu Asp Ser Leu Ala Tyr Glu Tyr
 245 250 255

Glu Arg Glu Gly Leu Tyr Glu Gln Ala Phe Gln Leu Leu Arg Arg Phe
 260 265 270

Val Gln Ala Glu Gly Arg Arg Ala Thr Leu Gln Arg Leu Val Glu Ala
 275 280 285

Leu Glu Glu Asn Glu Leu Thr Ser Leu Ala Glu Asp Leu Leu Gly Leu
 290 295 300

Thr Asp Pro Asn Gly Gly Leu Ala
 305 310

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1384 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..684

- (ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 1..684

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGC TTC CTC CAA GCC TAC CGC GAG GGG GCG CTG CGC ACC GCG CTG CAG	48
Gly Phe Leu Gln Ala Tyr Arg Glu Gly Ala Leu Arg Thr Ala Leu Gln	
1 5 10 15	
AGG TGC ATG GCC CCG GCG CTT GCC CAG GAA GCG CTG CGG TTG CAG CTG	96
Arg Cys Met Ala Pro Ala Leu Ala Gln Glu Ala Leu Arg Leu Gln Leu	
20 25 30	
GAG TTG CGT GCA GGT GCG GAG CAG CTG GAC AGT TGG CTG ACT GAT GAA	144
Glu Leu Arg Ala Gly Ala Glu Gln Leu Asp Ser Trp Leu Thr Asp Glu	
35 40 45	
GAG CGC TGT TTG AAT TAC ATC TTA GCC CAG AAG CCC GAC CGG CTC AGG	192
Glu Arg Cys Leu Asn Tyr Ile Leu Ala Gln Lys Pro Asp Arg Leu Arg	
50 55 60	
GAC GAG GAA CTC GCG GAG CTG GAG GAT GAG CTC TGC AAA CTG ACG TGT	240
Asp Glu Glu Leu Ala Glu Leu Glu Asp Glu Leu Cys Lys Leu Thr Cys	
65 70 75 80	

GAC TGC ACT GGC CAG GGT GGA GCC ATA CAG GTA GCT TCT GCA GGT TCG Asp Cys Thr Gly Gln Gly Gly Ala Ile Gln Val Ala Ser Ala Gly Ser	288
85 90 95	
AAG TTC CCG GTT TCC TCT CCG ACC GAG GAG AAA CCA CTG CCG GCC GCC Lys Phe Pro Val Ser Ser Pro Thr Glu Glu Lys Pro Leu Pro Ala Ala	336
100 105 110	
TGC CAG ACT TTT CTG TTC CAC GGG CAG CTC GTA GTG AAC CGG CCA CTG Cys Gln Thr Phe Leu Phe His Gly Gln Leu Val Val Asn Arg Pro Leu	384
115 120 125	
ACT CTT CAA GAC CAG CAG ACG TTT GCG CGC TCG GTG GGT CTC AAG TGG Thr Leu Gln Asp Gln Gln Thr Phe Ala Arg Ser Val Gly Leu Lys Trp	432
130 135 140	
CGC AGG GTG GGG CGC TCG CTG CAG CGT AAC TGT CGG GCA CTG AGA GAT Arg Arg Val Gly Arg Ser Leu Gln Arg Asn Cys Arg Ala Leu Arg Asp	480
145 150 155 160	
CCT GCC CTC GAC TCG CTG GCC TAC GAG TAT GAG CGT GAT GGG CTA TAC Pro Ala Leu Asp Ser Leu Ala Tyr Glu Tyr Glu Arg Asp Gly Leu Tyr	528
165 170 175	
GAG CAG GCC TTC CAG CTG CTG CGC CGT TTC ATG CAA GCC GAG GGC CGC Glu Gln Ala Phe Gln Leu Leu Arg Arg Phe Met Gln Ala Glu Gly Arg	576
180 185 190	
CGT GCC ACA CTG CAG CGC CTG GTG GAG GCG CTG GAG GAG AAC GAA CTC Arg Ala Thr Leu Gln Arg Leu Val Glu Ala Leu Glu Glu Asn Glu Leu	624
195 200 205	
ACT AGT CTA GCA GGA GGG ATC TTG TTG GGC CAG GCG GAG CCG GAT GGC Thr Ser Leu Ala Gly Gly Ile Leu Leu Gly Gln Ala Glu Pro Asp Gly	672
210 215 220	
GGC CTG GCC TAA GTCTAGTACT GTGGGGAAGG GCGGCCAACC AGCAGTTCAG Gly Leu Ala	724
225	
TGTTTGAAAC CCACGGGTGG CTGTTGGGGT ATTTTTTACC GCTGATGTTG TACTGTTGAC	784
CACTTTCCAT CTACTGGACT TGGAGAGCAT ACGCACGCCC CACCTAGCTG AGCTGCTGGA	844
GTGCAACTAA CTGCCCCCTCC CCCCCGCCCC CAGGAGTCAG GCAAGCAGCG CAGGGGTAAA	904
TCACTGATGA TCATACAAAA AGAGGACTTG CTGCAAAGAC CCTCTAAGTA CCCGGACCTT	964
CTGAAACCTA GTCAAGGTGC TACAAAACT GTCGGGAGCA GGATGACGAT TTTCCCCGCC	1024
CTTGGATATA CTCATCGTGG GACCGAAGCA CCTTGTCTGA GCGATAATAA AATGTAATC	1084
TTTTACAGAC TTGCGGAGAT GCTGAGGTCT AGACCTGGTT GGGGTTAGTC ACCTCAGTGG	1144
AATAGTGAGC CAGGTAGAGT AGGGAGTGGA GAGACAGGCA GGGTTCGGGT AGGGCCTTGA	1204
GGAAGGTGAG AGGAAGGGGT TGCTACCTGT CCTGTTAGTG AAGGATAACC GGGGGTTTGG	1264
TGAACCATCA TTACATTAGG TTTGGTTTTG TTTGGTGTGT GTATCTAAGT ATTGTGCTTT	1324
AAAACATCTA CCGTGTCTTG AATTAGAAAA TTAAATTTT AGCCAGAAAA AAAAAAAAAA	1384

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 227 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Gly Phe Leu Gln Ala Tyr Arg Glu Gly Ala Leu Arg Thr Ala Leu Gln
 1           5           10           15
Arg Cys Met Ala Pro Ala Leu Ala Gln Glu Ala Leu Arg Leu Gln Leu
          20           25           30
Glu Leu Arg Ala Gly Ala Glu Gln Leu Asp Ser Trp Leu Thr Asp Glu
          35           40           45
Glu Arg Cys Leu Asn Tyr Ile Leu Ala Gln Lys Pro Asp Arg Leu Arg
          50           55           60
Asp Glu Glu Leu Ala Glu Leu Glu Asp Glu Leu Cys Lys Leu Thr Cys
          65           70           75           80
Asp Cys Thr Gly Gln Gly Gly Ala Ile Gln Val Ala Ser Ala Gly Ser
          85           90           95
Lys Phe Pro Val Ser Ser Pro Thr Glu Glu Lys Pro Leu Pro Ala Ala
          100          105          110
Cys Gln Thr Phe Leu Phe His Gly Gln Leu Val Val Asn Arg Pro Leu
          115          120          125
Thr Leu Gln Asp Gln Gln Thr Phe Ala Arg Ser Val Gly Leu Lys Trp
          130          135          140
Arg Arg Val Gly Arg Ser Leu Gln Arg Asn Cys Arg Ala Leu Arg Asp
          145          150          155          160
Pro Ala Leu Asp Ser Leu Ala Tyr Glu Tyr Glu Arg Asp Gly Leu Tyr
          165          170          175
Glu Gln Ala Phe Gln Leu Leu Arg Arg Phe Met Gln Ala Glu Gly Arg
          180          185          190
Arg Ala Thr Leu Gln Arg Leu Val Glu Ala Leu Glu Glu Asn Glu Leu
          195          200          205
Thr Ser Leu Ala Gly Gly Ile Leu Leu Gly Gln Ala Glu Pro Asp Gly
          210          215          220
Gly Leu Ala
          225
  
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Ala Ser Met Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
 1           5           10
  
```

WHAT IS CLAIMED IS:

1. An isolated Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) having a sequence defined by SEQUENCE ID NO:2, or a
5 fragment of said TRADD having a TRADD-specific binding affinity.
2. An isolated Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 1 having a TRADD-specific transcriptional activation activity.
- 10 3. An isolated Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 1 having a TRADD-specific apoptosis inducing activity.
- 15 4. An isolated Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 1 comprising SEQUENCE ID NO:2, residues 195-305.
- 20 5. An isolated nucleic acid encoding a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 1.
- 25 6. An isolated nucleic acid encoding a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 2.
- 30 7. An isolated nucleic acid encoding a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 3.
8. An isolated nucleic acid encoding a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD) or fragment thereof according to claim 4.

9. An isolated nucleic acid capable of hybridizing with a nucleic acid having the sequence defined by SEQUENCE ID NO:1 under low stringency conditions defined by a hybridization buffer comprising 0% formamide in 0.9 M saline/0.09 M sodium citrate (SSC) buffer at a temperature of 37°C and remaining bound
5 when subject to washing at 42°C with the SSC buffer at 37°C.

10. An isolated nucleic acid capable of hybridizing with a nucleic acid having the sequence defined by SEQUENCE ID NO:1 under low stringency conditions defined by a hybridization buffer comprising 20% formamide in 0.9 M saline/0.09
10 M sodium citrate (SSC) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 2 X SSC buffer at 42°C.

11. A method of identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with Tumor necrosis factor
15 Receptor Associated Death Domain protein (TRADD)-dependent signal transduction, said method comprising the steps of:

forming a mixture comprising:

a TRADD or TRADD fragment according to claim 1,
a natural intracellular TRADD binding target, wherein said binding
20 target is capable of specifically binding said TRADD or TRADD fragment, and
a candidate pharmacological agent;

incubating said mixture under conditions whereby, but for the presence of said candidate pharmacological agent, said TRADD or TRADD fragment selectively binds said binding target;

25 detecting the presence or absence of specific binding of said TRADD or TRADD fragment to said binding target,

wherein the absence of said selective binding indicates that said candidate pharmacological agent is a lead compound for a pharmacological agent capable of disrupting TRADD-dependent signal transduction.

30

12. A method of identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with Tumor necrosis factor

Receptor Associated Death Domain protein (TRADD)-dependent signal transduction, said method comprising the steps of:

forming a mixture comprising:

a TRADD or TRADD fragment according to claim 4,

5 a natural intracellular TRADD binding target, wherein said binding target is capable of specifically binding said TRADD or TRADD fragment, and
a candidate pharmacological agent;

incubating said mixture under conditions whereby, but for the presence of said candidate pharmacological agent, said TRADD or TRADD fragment
10 selectively binds said binding target;

detecting the presence or absence of specific binding of said TRADD or TRADD fragment to said binding target,

wherein the absence of said selective binding indicates that said candidate pharmacological agent is a lead compound for a pharmacological agent capable of
15 disrupting TRADD-dependent signal transduction.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03591

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 14/47, 14/705; C12N 5/10, 15/12
US CL :435/6, 69.1. 252.3, 320.1; 530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 69.1. 252.3, 320.1; 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: tumor necrosis factor, TNF, receptor#, TNFR, death domain#.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X ----- P, Y	HSU et al. The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-kappaB Activation. Cell. 19 May 1995, Vol. 81, pages 495-504, see entire document.	1-10 ----- 11, 12
P, A	CHINNAIYAN et al. FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis. Cell. 19 May 1995, Vol. 81, pages 505-512, see entire document.	1-12
A	BOLDIN et al. Self-association of the "Death Domains" of p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects*. The Journal of Biological Chemistry. 06 January 1995, Vol. 270, No. 1, pages 387-391, see entire document.	1-12

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 JULY 1996

Date of mailing of the international search report

29 JUL 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN D. ULM

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*